Tuberculosis (TB) remains the leading infectious disease cause of mortality worldwide. A subset of individuals with sustained, heavy exposure to Mycobacterium tuberculosis (Mtb) do not develop detectable immune conversion by tuberculin skin test (TST) or interferon-gamma release assay (IGRA) and are described as TB resisters. The biological bases for this apparent resistance to infection are not well defined. The authors applied untargeted, high-resolution plasma metabolomics to determine whether systemic metabolic profiles differ between TB resisters and closely matched Mtb-infected contacts.
The study enrolled matched pairs across three countries: Brazil, India, and South Africa. The analysis included 269 TB resisters and 269 matched Mtb-infected close contacts. TB resisters were defined as highly exposed close contacts who either slept in the same room or spent at least five hours indoors per day with an infectious pulmonary TB index patient but remained negative by TST and IGRA. Matched Mtb-infected close contacts were persons who tested positive by TST or IGRA.
Plasma samples were analyzed using untargeted high-resolution liquid chromatography–mass spectrometry. Metabolome-wide association studies (MWAS) compared paired samples using paired t-tests to assess differences between TB resisters and matched infected contacts. Identified features were evaluated for pathway enrichment. For metabolites with confirmed chemical identities, concentrations were reported and adjusted for multiple comparisons; a false discovery rate (FDR) threshold of 0.2 was applied for reporting confirmed metabolite differences in the manuscript.
Across the cohort, 1,787 metabolomic features showed nominal differences between TB resisters and matched Mtb-infected contacts (p < 0.05). Pathway enrichment analysis in the overall cohort highlighted fructose and mannose metabolism and bile acid biosynthesis as differing between groups. In the Brazil cohort specifically, enrichment analyses identified differences in lipid-related pathways.
Among metabolites with confirmed chemical identities and meeting the reporting threshold (FDR = 0.2), the study reported quantitative differences in four metabolites:
These identified metabolites were presented as individual, confirmed chemical species differing between groups; the report also emphasizes broader pathway-level differences (fructose/mannose metabolism, bile acid biosynthesis, and lipid pathways in Brazil).
Plasma metabolomic profiles differed between TB resisters and matched Mtb-infected close contacts enrolled across Brazil, India, and South Africa. The authors interpret these findings to indicate that systemic metabolic differences are associated with resistance to Mtb infection. Specific pathways (fructose and mannose metabolism, bile acid biosynthesis) and particular metabolites (glyceric acid, hydroxyproline, butyrobetaine, homogentisate) were highlighted as differing between groups. The article is a preprint and has not undergone peer review; the authors note that these results suggest candidate metabolic signatures for further study rather than immediate clinical application.
The study reports institutional review board approvals from multiple participating institutions, including Emory University, Johns Hopkins University, Vanderbilt University, Rutgers University, Comissao Nacional De Etica em Pesquisa (CONEP), University of the Witwatersrand, Byramjee Jeejeebhoy Government Medical College, Jawaharlal Institute of Postgraduate Medical Education and Research, Bhagwan Mahavir Medical Research Centre, and the National Institute for Research in Tuberculosis (Chennai).
Deidentified participant-level data are not publicly available because of participant consent, IRB requirements, and cross-cohort data-use restrictions. Requests for access may be submitted to the corresponding author and will be considered subject to approvals and data-use agreements. Summary-level metabolomics results are provided in the Supplementary Materials of the preprint.
The reported funders include the US National Institutes of Health–National Institute of Allergy and Infectious Disease (several grants cited) and institutional centers such as the Emory/Georgia Tuberculosis Research Advancement Center and other listed research cores. The authors declared no competing interests. The manuscript is available as a medRxiv preprint and has not been certified by peer review; it should not be used to guide clinical practice.